Placenta Accreta ManagementNCT07236710
Observation of Strategies in Placenta Accreta Spectrum Management
An observational study of Placenta Accreta Management, run by Assiut University.
Trial summary
Placenta accreta spectrum (PAS) disorders represent a significant obstetric challenge, characterized by abnormal adherence of the placenta to the uterine wall, leading to potentially life-threatening hemorrhage (ACOG 2020; RCOG 2018; Jauniaux 2019) during delivery. Read more about this study
- Who is it for?
- Ages 18 to 50 years, women only
- Conditions the study is for
- Placenta Accreta Management
- How many people
- 300 participants
- Where
- No sites listed yet
- Study dates
- 20 Dec 2025to 30 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- Adult
Study population: All pregnant women diagnosed with placenta accreta spectrum disorders during the study period
Who may be able to join
- - Women diagnosed with PAS (accreta, increta, percreta).
- Deliveries conducted at Women's Health Hospital.
- Age 18-50 years.
- Availability of complete medical records and operative details.
Who cannot join
- - Patients with incomplete records or missing surgical reports.
- Cases managed outside the hospital.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Evolving Strategies in Placenta Accreta Spectrum Management: A Ten-Year Institutional Review
- Placenta accreta spectrum (PAS) disorders represent a significant obstetric challenge, characterized by abnormal adherence of the placenta to the uterine wall, leading to potentially life-threatening hemorrhage (ACOG 2020; RCOG 2018; Jauniaux 2019) during delivery. PAS includes placenta accreta (attachment to the myometrium), increta (invasion into the myometrium), and percreta (penetration through the uterine serosa, often involving adjacent organs). The incidence of PAS is rising globally, largely attributed to the increased rates of cesarean section and uterine surgeries (Bowman 2021).
Effective management of PAS is crucial to prevent severe maternal morbidity and mortality. The cornerstone of management remains surgical intervention, with cesarean hysterectomy being the traditional gold standard (Eller 2009; ACOG 2020), especially in cases of extensive invasion. However, conservative and fertility-preserving surgical techniques have emerged in recent years as viable alternatives in selected cases (Jauniaux 2019).
Read more
In Assiut university hospital, diverse surgical approaches are practiced depending on the extent of placental invasion, surgeons expertise, and patient fertility desires. These include cesarean hysterectomy, segmental uterine resection, the Triple-P procedure, and uterus-preserving methods such as leaving the placenta in situ. (ijrcog) A notable contribution to conservative PAS management in Egypt is the Placental Pouch Closure technique. This technique involves careful resection of the invaded uterine wall followed by multilayered closure of the resulting myometrial defect (the "placental pouch"), thereby controlling hemorrhage while preserving uterine integrity.
(Zahran et al. 2020) .
- This retrospective study aims to evaluate the pattern and outcomes of various surgical approaches used in the management of placenta accreta spectrum disorders over a 10-year period at a Assiut university hospital. Special attention will be paid to the adoption, safety, and effectiveness of conservative techniques
- Conditions
- Placenta Accreta Management
What is being measured
The primary outcome is the main question the study is designed to answer.
Patterns of management over time
Patterns of management of placenta Accreta in retrospective way on the last 10 years
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2025
- Study start20 Dec 2025 (estimated)
- Primary completion20 Oct 2027 (estimated)
- Study completion30 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Placenta Accreta ManagementStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Ayman Saad zaghlol Abdallah, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07236710
- Sponsor's protocol ID
- placenta Accreta management
- Status last verified
- Nov 2025
- First submitted
- 15 Nov 2025
- Last updated
- 19 Nov 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Eller AG, Porter TF, Soisson P, Silver RM. Optimal management strategies for placenta accreta. BJOG. 2009 Apr;116(5):648-54. doi: 10.1111/j.1471-0528.2008.02037.x. Epub 2009 Feb 4.
PubMed 19191778Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2019 Jul;146(1):20-24. doi: 10.1002/ijgo.12761.
PubMed 31173360Jauniaux E, Alfirevic Z, Bhide AG, Belfort MA, Burton GJ, Collins SL, Dornan S, Jurkovic D, Kayem G, Kingdom J, Silver R, Sentilhes L; Royal College of Obstetricians and Gynaecologists. Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green-top Guideline No. 27a. BJOG. 2019 Jan;126(1):e1-e48. doi: 10.1111/1471-0528.15306. Epub 2018 Sep 27. No abstract available.
PubMed 30260097
Study at a glance
From the registry record, last updated by the sponsor on 19 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evolving Strategies in Placenta Accreta Spectrum Management: A Ten-Year Institutional Review
- ClinicalTrials.gov ID
- NCT07236710
- Acronym / sponsor ID
- placenta Accreta management
- Conditions
- Placenta Accreta Management
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 20 Dec 2025 (estimated)
- Primary completion
- 20 Oct 2027 (estimated)
- Study completion
- 30 Dec 2027 (estimated)
- First posted
- 19 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Placenta accreta spectrum (PAS) disorders represent a significant obstetric challenge, characterized by abnormal adherence of the placenta to the uterine wall, leading to potentially life-threatening hemorrhage (ACOG 2020; RCOG 2018; Jauniaux 2019) during delivery. PAS includes placenta accreta (attachment to the myometrium), increta (invasion into the myometrium), and percreta (penetration through the uterine serosa, often involving adjacent organs). The incidence of PAS is rising globally, largely attributed to the increased rates of cesarean section and uterine surgeries (Bowman 2021).
Effective management of PAS is crucial to prevent severe maternal morbidity and mortality. The cornerstone of management remains surgical intervention, with cesarean hysterectomy being the traditional gold standard (Eller 2009; ACOG 2020), especially in cases of extensive invasion. However, conservative and fertility-preserving surgical techniques have emerged in recent years as viable alternatives in selected cases (Jauniaux 2019).
In Assiut university hospital, diverse surgical approaches are practiced depending on the extent of placental invasion, surgeons expertise, and patient fertility desires. These include cesarean hysterectomy, segmental uterine resection, the Triple-P procedure, and uterus-preserving methods such as leaving the placenta in situ. (ijrcog) A notable contribution to conservative PAS management in Egypt is the Placental Pouch Closure technique. This technique involves careful resection of the invaded uterine wall followed by multilayered closure of the resulting myometrial defect (the "placental pouch"), thereby controlling hemorrhage while preserving uterine integrity.
(Zahran et al. 2020) .
- This retrospective study aims to evaluate the pattern and outcomes of various surgical approaches used in the management of placenta accreta spectrum disorders over a 10-year period at a Assiut university hospital. Special attention will be paid to the adoption, safety, and effectiveness of conservative techniques
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Age groups
- Adult
- Study population
- All pregnant women diagnosed with placenta accreta spectrum disorders during the study period
Key inclusion criteria (4 listed)
- - Women diagnosed with PAS (accreta, increta, percreta).
- Deliveries conducted at Women's Health Hospital.
- Age 18-50 years.
- Availability of complete medical records and operative details.
Key exclusion criteria (2 listed)
- - Patients with incomplete records or missing surgical reports.
- Cases managed outside the hospital.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Patterns of management over time
Time frame: 10 years
Patterns of management of placenta Accreta in retrospective way on the last 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Nov 2025.
- Results publication: PubMed 19191778Eller AG, Porter TF, Soisson P, Silver RM. Optimal management strategies for placenta accreta. BJOG. 2009 Apr;116(5):648-54. doi: 10.1111/j.1471-0528.2008.02037.x. Epub 2009 Feb 4.
- Results publication: PubMed 31173360Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2019 Jul;146(1):20-24. doi: 10.1002/ijgo.12761.
- Results publication: PubMed 30260097Jauniaux E, Alfirevic Z, Bhide AG, Belfort MA, Burton GJ, Collins SL, Dornan S, Jurkovic D, Kayem G, Kingdom J, Silver R, Sentilhes L; Royal College of Obstetricians and Gynaecologists. Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green-top Guideline No. 27a. BJOG. 2019 Jan;126(1):e1-e48. doi: 10.1111/1471-0528.15306. Epub 2018 Sep 27. No abstract available.
Related trials for Placenta Accreta Management
Not yet recruitingObservational study
Total Lower Uterine Segmentectomy With Adjunctive Mechanical Towel Compression for the Surgical Management of Placenta Accreta Spectrum Disorders
Placenta Accreta Management
Recruiting
Comparison Between 3 Conservative Surgeries for Placenta Accreta Spectrum
Placenta Accreta Spectrum
Recruiting
Uterine Preservation in the Management of Placenta Accreta Spectrum Disorders
Placenta Accreta Spectrum
Active, not recruiting
Conservative Management for PAS Pilot
Placenta Accreta
Not yet recruiting
Conservative Management of Placenta Accreta Spectrum Using Kasr Al-Ainy Technique With or Without Hayman Sutures
Placenta Accreta Spectrum
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Placenta Accreta Management, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mohamed Ayman Ayman, Master (+201103934356, mohamedayman.g955@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patterns of management over time (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07236710, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2025.